Author: Hlushko, Raman ; Lazaro, Glorie G. ; Yunus, Abdul S. ; Dimitrov, Antony S. ; Andrianov, Alexander K. ; Promeneur, Dominique ; Marin, Alexander ; Leyva-Grado, Victor H. ; Broder, Christopher C. ; Hamm, Stefan ; Luckay, Amara

The ultimate vaccine against infections caused by Nipah virus should be capable of providing protection at the respiratory tract-the most probable port of entry for this pathogen.Intranasally delivered vaccines, which target nasal-associated lymphoid tissue and induce both systemic and mucosal immunity, are attractive candidates for enabling effective vaccination against this lethal disease.Herein, the water-soluble polyphosphazene delivery vehicle assembles into nanoscale supramol. constructs with the soluble extracellular portion of the Hendra virus attachment glycoprotein-a promising subunit vaccine antigen against both Nipah and Hendra viruses.These supramol. constructs signal through Toll-like receptor 7/8 and promote binding interactions with mucin-an important feature of effective mucosal adjuvants.High mass contrast of phosphorus-nitrogen backbone of the polymer enables a successful visualization of nanoconstructs in their vitrified state by cryogenic electron microscopy.Here, we characterize the self-assembly of polyphosphazene macromol. with biol. relevant ligands by asym. flow field flow fractionation, dynamic light scattering, fluorescence spectrophotometry, and turbidimetric titration methods.Furthermore, a polyphosphazene-enabled intranasal Nipah vaccine candidate demonstrates the ability to induce immune responses in hamsters and shows superiority in inducing total IgG and neutralizing antibodies when benchmarked against the resp. clin. stage alum adjuvanted vaccine.The results highlight the potential of polyphosphazene-enabled nanoassemblies in the development of intranasal vaccines.

01 Aug 2022·Virology

Corrigendum to “Newcastle disease virus vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs” [Virology 432 (2012) 327–335]

Author: Ge, Jinying ; Wu, Chao ; Yang, Chinglai ; Chen, Hualan ; Bu, Zhigao ; Wang, Xijun ; Chen, Weiye ; Wen, Zhiyuan ; Kong, Dongni ; Su, Hua

01 Jun 2022·Comparative Immunology, Microbiology and Infectious Diseases

Serosurvey for Nipah virus in bat population of southern part of India

Letter

Author: Holeppanavar, Manjunath ; Gopale, Sanjay ; Mathapati, Basavaraj ; Balasubramanian, R ; Suryawanshi, Annasaheb T ; Gokhale, Mangesh ; Mohandas, Sreelekshmy ; Yadav, Pragya D ; Jain, Rajlaxmi ; Shete, Anita M ; Sudeep, A B ; Dhaigude, Sachin ; Patil, Deepak Y ; Sawant, Pradeep ; Patil, Dilip R ; Chopade, Ganesh ; Ullas, P T ; Mourya, Devendra T

Nipah virus (NiV) is one of the priority pathogens with pandemic potential. Though the spread is far slower than SARS-CoV-2, case fatality is the biggest concern. Fruit bats belonging to genus Pteropus are identified to be the main reservoir of the virus causing sporadic cases and outbreaks in Malaysia, Bangladesh and India. The sudden emergence of Nipah in Kerala, India during 2018-2019 has been astonishing with respect to its introduction in the unaffected areas. With this, active Nipah virus surveillance was conducted among bat populations in Southern part of India viz., Karnataka, Kerala, Tamil Nadu, Telangana, Puducherry and Odisha during January-November 2019. Throat swabs/rectal swabs (n = 573) collected from Pteropus medius and Rousettus leschenaultii bat species and sera of Pteropus medius bats (n = 255) were screened to detect the presence of Nipah viral RNA and anti-Nipah IgG antibodies respectively. Of 255 P. medius bats sera samples, 51 bats (20%) captured from Karnataka, Kerala, Tamil Nadu and Puducherry demonstrated presence of anti-Nipah IgG antibodies. However, the presence of virus couldn't be detected in any of the bat specimens. The recent emergence of Nipah virus in Kerala in September 2021 warrants further surveillance of Nipah virus among bat populations from the affected and remaining states of India.

100 Deals associated with Nipah vaccine (Janssen Vaccines/University of Oxford)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Henipavirus Infections	Preclinical	GB	Janssen Vaccines Corp.	-
Henipavirus Infections	Preclinical	GB	University of Oxford	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Nipah vaccine (Janssen Vaccines/University of Oxford)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation